








objectives

- 1. Some techniques/skills for critical appraisal
 - 1. Generic tools
 - 2. Specific tools
- 2. to help you plan your own 1 hour teaching of critical appraisal
- 3. Have some fun and make teaching EBP seem easy









Sickness in Salonica: my first, worst, and most successful clinical trial-1941.

"... I recruited 20 young prisoners... I gave them a short talk about my medical hero James Lind and they agreed to co-operate in an experiment. I cleared two wards. I numbered the 20 prisoners off: odd numbers to one ward and evens to the other.

Each man in one ward received two spoonfuls of yeast daily. The others got one tablet of vitamin C from my "iron" reserve. The orderlies co-operated magnificently . . . They controlled fluid intake and measured frequency of urination.

... There was no difference between the wards for the first two days, but the third day was hopeful, and on the fourth the difference was conclusive... there was less oedema in the "yeast" ward. I made careful notes of the trial and immediately asked to see the Germans."

A. L. Cochrane (Br Med J 1984; 289: 1726-7)

"It could be argued that the trial was randomised and controlled, although this last was somewhat inadequate. In those early days, when the randomised controlled trial was little known in medicine, this was something of an achievement."

BRITISH MEDICAL **JOURNAL**

LONDON SATURDAY OCTOBER 30 1948

STREPTOMYCIN TREATMENT OF PULMONARY TUBERCULOSIS A MEDICAL RESEARCH COUNCIL INVESTIGATION

The following gives the short-term results of a controlled investigation into the effects of streptomycin on one type of pulmonary tuberculosis. The inquiry was planned and directed by the Streptomycin in Tuberculosis Trails Committee, composed of the following members: Dr. Geoffrey Marshall (chairman), Professor J. W. S. Blacklock, Professor C. Cameron, Professor N. B. Capon, Dr. R. Cruickshank, Professor J. H. Gaddum, Dr. F. R. G. Heaf, Professor A. Bradford Hill, Dr. L. E. Houghton, Dr. J. Clifford Holy-Professor H. Raistrick, Dr. J. G. Scadding, Professor W. H. Tytler, Professor G. S. Wilson, and Dr. P. D'Arcy Hart (secretary). The centres at which the work was carried out and the specialists in charge of patients and pathological work were as follows:

thological work were as follows:

Brompton Hospital, London.—Clinician: Dr. J. W. Crofton, Streptomycin Registrar (working under the direction of the honorary staff of Brompton Hospital).

Pathologists: Dr. J. W. Clegg, Dr. D. A. Mitchison. Colindade Hospital (L.C.C.), London.—Clinicians: Dr. W. Santon Gilmour, Dr. A. M. Reevie; J. V. Hurford, Dr. B. J. Douglas Smith, Dr. W. E. Snell: Harbologists: (Central Public Health Laboratory): Dr. G. B. Forbes, Dr. H. D. Holt.

Harefield Hospital (M.C.C.), Harefield, Middlesex.—Clinicians: Dr. W. Santon Gilmour, Dr. A. Mohun. P. Clinicians: Dr. W. Santon Gilmour, Dr. A. M. Reevie; Pathologists: Dr. J. M. Alston, Dr. A. Mohun. P. Clinicians: Dr. W. Santon Gilmour, Dr. A. M. Reevie; Pathologists: Dr. J. M. Alston, Dr. A. Mohun. P. Clinicians: Dr. W. Santon Gilmour, Dr. A. M. Reevie; Pathologists: Dr. J. M. Alston, Dr. A. Mohun. P. Clinicians: Dr. W. Santon Gilmour, Dr. A. M. Reevie; Pathologists: Dr. J. M. Alston, Dr. A. Mohun. P. Clinicians: Dr. W. Santon Gilmour, Dr. A. M. Reevie; Pathologists: Dr. J. M. Alston, Dr. A. Mohun. P. Clinicians: Dr. W. Santon Gilmour, Dr. A. M. Reevie; Pathologists: Dr. J. M. Alston, Dr. A. M. Reevie; Pathologists: Dr. J. M. Alston, Dr. A. M. Reevie; Pathologists: Dr. J. W. Leeding, P. Clinicians: Dr. W. Santon Gilmour, Dr. A. M. Reevie; Pathologists: Dr. J. M. Alston, Dr. A. M. Reevie; Pathologists: Dr. J. M. Alston, Dr. A. Mohun. P. Clinicians: Dr. W. Santon Gilmour, Dr. A. M. Reevie; Pathologists: Dr. J. M. Alston, Dr. A. M. Reevie; Pathologists: Dr. J. M. Alston, Dr. A. M. Reevie; Pathologists: Professor W. M. Pathologists: Pr


ramologist: Dr. E. Nassau.

The clinicians of the centres met periodically as a working subcommittee under the chairmanship of Dr. Geoffrey Marshall; so also did the pathologists under the chairmanship of Dr. R. Cruickshank. Dr. Marc Daniels, of the Council's scientific staff, was responsible for the clinical co-ordination of the trials, and he also prepared the report for the Committee, with assistance from Dr. D. A. Mitchison on the analysis of laboratory results. For the purpose of final analysis the radiological flaings were assessed by a panel composed of Dr. L. G. Blair, Dr. Peter Kerley, and Dr. Geoffrey S. Todd.

Introduction

When a special committee of the Medical Research Council undertook in September, 1946, to plan clinical trials of streptomycin in tuberculosis the main problem faced was that of investigating the effect of the drug in pulmonary tuberculosis. This antibiotic had been discovered two years previously by Waksman (Schatz, Bugie, and Waksman, 1944); in the intervening period its power of inhibiting

• The problem...





Engage your audience

- People respond to people. Rarely will you hold the attention of your audience through content alone.
- To engage the audience you need to interact with them, share your warm personality and gentle sense of humour and invite them to participate in some way.

http://www.skillsworkshop.net/a1.html

Why is this talk important to you?



You are here because?....

- A. Part of the MSc but no intention of teaching
- B. You've never taught critical appraisal before but want to
- C. You already teach some but want to pick up new skills or refine yours
- D. You already teach it to the highest level and came to share some skills with others
- E. You made a terrible mistake on the application form and thought this was a weeks course on the History of Ancient and Medieval architecture....







Know your audience


- Who are you teaching critical appraisal to?
- What are your learners objectives?
- Why are they here?








Try and create a safe environment





• Specific tools...content

What's so special about RCTs?

- most rigorous way of determining:
 - a cause-effect relation exists between treatment and outcome and
 - for assessing the cost effectiveness of a treatment
- distributing the characteristics of patients that may influence the outcome randomly between the groups-no systematic differences between intervention groups


What's so special about RCTs?

- patients and trialists should remain unaware of which treatment was given until the study is completed to avoid influencing the result
- both arms treated identically except for the intervention of interest – estimating the size of the difference in predefined outcomes between intervention groups




Limitations of RCTs

- Excellent vs Poor RCTs quality varies
 - Impact on interpretation of result (external validity)?
- · Expensive and time consuming
 - £250k £millions over 2-5 years+
- May not always be the right study design to answer that question



Critical appraisal....



...is like being a detective.

You need the skills to think broadly and detect the flaws that might distract you from finding the true answer.

Risk of Bias – internal validity

- The degree to which the result is skewed away from the truth
- Causal inferences from randomised trials can, however, be undermined by flaws in design, conduct, analyses, and reporting
- leading to underestimation or overestimation of the true intervention effect

Confounding factors

• Other patient features/causal factors, apart from the one being measured, that can affect the outcome of the study e.g..









Internal validity

- extent to which observed treatment effects can be ascribed to differences in treatment and not confounding, thereby allowing the inference of causality to be ascribed to a treatment.¹
- Systematic error (bias) could threaten the internal validity of trials, and all efforts should be made to minimise these in the design, conduct, and analysis of studies.²

http://www.bmj.com/content/344/bmj.e1004
 http://www.ncbi.nlm.nih.gov/pubmed/1872852

	Types of bias
Type of bias	Description
Selection bias	Systematic differences between baseline characteristics of the groups that are compared.
Performance bias	Systematic differences between groups in the care that is provided, or in exposure to factors other than the interventions of interest
Attrition bias	Systematic differences between groups in withdrawals from a study
Detection bias	Systematic differences between groups in how outcomes are determined
Reporting bias	Systematic differences between reported and unreported findings






























PICO


- Population/problem
 - Adults with mild to moderate depression
- Intervention
 - Regular physical activity
- Comparator
 - "Usual care"/no physical activity
- Outcome
 - Improvement in symptoms of mild to moderate depression





	Levels	s of evi	idence tab	oles	
Oxford Centre for Evi	dence-Based Medicine 2011 Leve	els of Evidence	Step 3	Step 4	Step 5 (Level 5)
	(Level 1*) Local and current random sample	(Level 2*) Systematic review of surveys	(Level 3*) Local non-random sample**	(Level 4*) Case-series**	n/a
problem?	surveys (or censuses)	that allow matching to local circumstances**	Local non-random sample	Case-series**	пуа
Is this diagnostic or monitoring test accurate? (Diagnosis)	Systematic review of cross sectional studies with consistently applied reference standard and blinding	Individual cross sectional studies with consistently applied reference standard and blinding	Non-consecutive studies, or studies without consistently applied reference standards**	Case-control studies, or "poor or non-independent reference standard**	Mechanism-based reasoning
What will happen if we do not add a therapy? (Prognosis)	Systematic review of inception cohort studies	Inception cohort studies	Cohort study or control arm of randomized trial*	Case-series or case- control studies, or poor quality prognostic cohort study**	n/a
Does this intervention help? (Treatment Benefits)	Systematic review of randomized trials or <i>n</i> -of-1 trials	Randomized trial or observational study with dramatic effect	Non-randomized controlled cohort/follow-up study**	Case-series, case-control studies, or historically controlled studies**	Mechanism-based reasoning
What are the COMMON harms? (Treatment Harms)	Systematic review of randomized trials, systematic review of nested case-control studies, n-of-1 trial with the patient you are raising the question about, or observational study with dramatic effect	Individual randomized trial or (exceptionally) observational study with dramatic effect	Non-randomized controlled controllow-up study (post-marketing surveillance) provided there are sufficient numbers to rule out a common harm. (For long-term harms the duration of follow-up must be sufficient.)**	Case-series, case-control, or historically controlled studies**	Mechanism-based reasoning
What are the RARE harms? (Treatment Harms)	Systematic review of randomized trials or <i>n</i> -of-1 trial	Randomized trial or (exceptionally) observational study with dramatic effect			
Is this (early detection) test worthwhile? (Screening)	Systematic review of randomized trials	Randomized trial	Non -randomized controlled cohort/follow-up study**	Case-series, case-control, or historically controlled studies**	Mechanism-based reasoning








Some search skills











Assessing risk of bias for an RCT THERAPY STUDY: Are the results of the trial valid? (Internal Validity) What question did the study ask? Patients Intervention Comparison Outcome(s) I.a. R - Was the assignment of patients to treatments randomised? What is best? Centraised compair randomisation is deal and often used in multicentred trials. Smaller trials may use an foliable trial property of the study of t

RRAMMbo tool - Risk of Bias

		Type of bias
Recruitment	Were the subjects representative of the target population?	Selection bias Other sources of bias
Randomisation Allocation	How was randomisation carried out? Was allocation concealed?	Selection bias
Maintenance	Were the groups equal at the start? And maintained through equal management and f/u?	Performance bias Attrition bias
Measurement- Blinding	Were the outcomes measured with blinded assessors/participants	Performance bias
Objective outcomes (Measurement)	Were there differences in how outcomes were determined	Detection bias



Selection bias



- systematic differences between baseline characteristics of the groups
- Adequate randomisation
 - -1) Sequence generation
 - 2) Allocation concealment

Sequence generation (selection bias)

Low risk of bias

- random number table
- Using a computer random number generator
- Coin tossing
- Shuffling cards or envelopes
- · Throwing dice
- · Drawing of lots

High risk of bias

- Sequence generated by a a non-random component e.g
 - odd or even date of
 - birth date (or day) of admission
 - hospital or clinic record number
- · judgement of the clinician
- preference of the participant
- · availability of the intervention

Allocation concealment (selection bias)

Low risk

- Central allocation (including telephone, web-based and pharmacy-controlled randomization
- Sequentially numbered drug containers of identical appearance
- Sequentially numbered, opaque, sealed envelopes.

High risk

- Alternation or rotation
- open random allocation schedule (e.g. a list of random numbers)
- envelopes were unsealed or non-opaque

Performance bias



- Systematic differences between groups in the care that is provided, or in exposure to factors other than the interventions of interest.
- Blinding of participants, personnel and outcome assessors

Blinding (Performance bias)

Low risk of bias

- No blinding, but outcome and the outcome measurement are not likely to be influenced
- Blinding of participants and personnel
- blinding of participants or personnel but outcome assesment unlikely to have been affected

High risk of bias

- No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding
- Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken
- No blinding

Attrition bias



- Systematic differences between groups in withdrawals from a study.
- Attrition refers to situations in which outcome data are not available
- Exclusions refer to situations in which some participants are omitted from reports of analyses, despite outcome data being available to the trialists.

Incomplete reporting (Attrition bias)

Low risk of bias

- · No missing outcome data
- Reasons for missing outcome data unlikely to be related to true outcome
- Methodology ITT

High risk of bias

- Reason for missing outcome data likely to be related to true outcome,
- "As-treated' analysis done with substantial departure of the intervention received from that assigned at randomization

Intention to treat (ITT)

- participants in trials should be analysed in the groups to which they were randomized, regardless of whether they received or adhered to the allocated intervention.
- 2 issues:
 - estimate the effects in practice
 - Not a subgroup who adhere to the intervention
 - "Per protocol" can overestimate effects
 - Loss to follow up
 - ITT ensures the outcome is still measured on these patients

Reporting bias



- systematic differences between reported and unreported findings.
- E.g publication bias, more likely to report significant differences between intervention groups than non-significant differences.

Selective outcome reporting (Reporting bias)

Low risk of bias

- The study protocol is available and all of the study's prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way
- The study protocol is not available but it is clear that the published reports include all expected outcomes

High risk of bias


- Not all of the study's prespecified primary outcomes have been reported
- One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified
- One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);
- outcomes of interest in the review are reported

Other biases




- Trial designs
 - carry-over in cross-over trials
 - recruitment bias in cluster-randomized trials
 - E.g participants may know already which group they have been allocated to because everyone in that "cluster" gets the same intervention.

Cochrane risk of bias table







Recruitment (selection bias)

- Were the subjects representative of the target population?
 - What were the inclusion & exclusion criteria?
 - Were they appropriate?
 - How/where were they recruited from?
- Methods Recruitment of participants and baseline assessment & Results 1st para



Allocation (selection bias)

- Were the groups comparable at the start?
 - "Table 1"
- Randomised appropriately?
- Allocation to group concealed beforehand?
- Methods: Randomisation, concealment, and blinding and "Table 1"



Maintenance


- Were both groups comparable throughout the study?
 - Managed equally bar the intervention?
 - What was the intervention?
 - What was the comparator?
- Methods: Follow up and Intervention and comparator (usual care)



Adequate follow up? (Attrition bias)

- How many people were lost to f/u?
- Why were they lost to f/u?
- Did the researchers use an intention to treat (ITT) principle?
 - Once a participant is randomised, they should be analysed to the group they were assigned to
- Figure 1 and Statistical analysis






Measurement – blinding (Performance bias)

- Were the outcomes measured blindly by researchers and participants?
 - Double blinding (low risk of bias)
 - Subjects and investigators (outcome assessors) both unaware of allocation
 - Single blinded (moderate risk of bias)
 - Either subjects OR investigators (outcome assessors) unaware of allocation
 - No blinding (high risk of bias)
 - Subjects and investigators aware of allocation
- Methods: Randomisation, concealment, and blinding





P - values and CI

- P values
 - Measure of probability that a result is due to chance
 - The smaller the value (usually P<0.05) less likely due to chance
- Confidence intervals
 - Estimate of the range of values that are likely to include the real value
 - 95% chance of including the real value
 - Narrower the range>more reliable
 - If value does not cross 0 for a difference, or 1 for a ratio then pretty sure result is real (p<0.05)


Measurement - outcomes

- What were the outcomes?
 - Primary
 - Secondary
 - Were they appropriate?
- How were the results reported?
- Were they significant?
- Methods: Outcomes and Results









Outcomes

	Measure	Narrative	Numerical
Primary outcome: short term symptoms of depression	Beck depression inventory score	no evidence that participants in the intervention group had a better outcome at four months than those in the usual care group	difference in mean score of -0.54 (95% confidence interval -3.06 to 1.99; P=0.68)
Secondary outcomes Longer term symptoms of depression	Beck depression inventory score	no evidence of a difference between the treatment groups over the duration of the study	difference in mean Beck depression inventory score -1.20,95% confidence interval-3.42 to 1.02;P=0.29
Anti- depressant use	participants reporting use of antidepressants	no evidence to suggest any difference between the groups at either the four month follow-up point or duration of trial	adjusted odds ratio 1.20, 95% confidence interval 0.69 to 2.08; P=0.52
Physical activity	self completion seven day recall diary	there was some evidence for a difference in reported physical activity between the groups at four months post-randomisation	adjusted odds ratio 1.58, 0.94 to 2.66; P=0.08)

Conclusions of the study

BMJ 2012;344:e2758 doi: 10.1136/bmj.e2758 (Published 6 June 2012)

Page 7 of 13

RESEARCH

What is already known on this topic

Depression is a leading contributor to disability in the United Kingdom and is associated with a decrement of health greater than many other chronic diseases

Many patients and healthcare professionals would like an effective and accessible non-drug treatment for depression

Numerous studies have reported the positive effects of physical activity but most of the current evidence originates from small non-clinical samples using interventions that are not practicable in healthcare settings

What this study adds

A physical activity intervention in addition to usual care did not improve symptoms of depression or reduce the use of antidepressants compared with usual care alone

The intervention increased self reported physical activity and this effect was sustained for 12 months

Clinicians and policy makers should alert people with depression that advice to increase physical activity will not increase their chances of recovery from depression

27 Pavey TG, Taylor AH, Fox KR, Hillsdon M, Anokye N, Campbell JL, et al. Effect of exercise referral schemes in primary care on physical activity and improving health outcomes: systematic review and meta-analysis. *BM*, 2011;343:d468.2

28 Ekkekakis P, Hall EE, Petruzzello SJ. Variation and homogeneity in affective responses to physical activity of varying intensities: an alternative perspective on dose-response based on evolutionary considerations. *J Sports Sci* 2005;32477-500.


29 Searis A Calnan M Lewis G. Camobell J. Taylor A. Turner K. Patients' views of physical activity.

External validity/applicability





Would you advocate exercise for depression based on this study?











Summary – delivering an EBM teaching session in 1h(~)

00:00	Start	
~00:10	Know and engage with your audience Set the scene	
~00:15	Ask a clinical question: PICO	
~00:20	Brief overview of searching skills Identify a paper related to your PICO	
~00:30	Critically appraise the paper – use tools to help	
~00:50	Overall conclusions of the paper (Internal validity)	
~00:55	Will the results of this paper change my practice? (External validity)	
~01:00	Sum up, self directed learning, close	







Make it fun and try new things



kamal.mahtani@phc.ox.ac.uk





Useful resources

- Centre For Evidence Based Medicine http://www.cebm.net/
- BMJ Evidence Centre
 http://group.bmj.com/products/evidence-centre
- EBM McMaster, Canada <u>http://ebm.mcmaster.ca/</u>

Odds ratio

- odds that an outcome will occur given a particular exposure, compared to the odds of the outcome occurring in the absence of that exposure
- Interpreting OR
 - OR=1 Exposure does not affect odds of outcome
 - OR>1 Exposure associated with higher odds of outcome
 - OR<1 Exposure associated with lower odds of outcome
- E.g.... OR = 1.46
 - Odds of having the outcome are 1.46 higher in the exposed group vs control group

Odds ratio

Outcome of interest

Exposure of interest

	+	1
+	а	b
-	С	d

$$OR = \frac{a/c}{b/d}$$

Relative Risk or Risk Ratio

- the risk of the event in one group divided by the risk of the event in the other group
- Interpreting RR
 - RR =1 Exposure does not affect risk of outcome
 - Is the treatment intended to prevent an undesirable outcome?
 - RR < 1Exposure reduces the risk of the event
 - RR > 1 Exposure increases the risk of the event (possible treatment harm, adverse events)
 - Is the treatment intended to promote an outcome? (e.g. disease remission)
 - RR < 1Exposure reduces the risk of the event (disease remission)
 - RR > 1 Exposure increases the risk of the event (disease remission)

E.g.... RR = 0.46

 Risk of getting the outcome with the exposure was 0.46 of that in the control group

RR v OR

- Often similar when event rate is low (<10%) or treatment effect is small (close to 1)
- As event rate increases (>10%)

Relative Risk or Risk Ratio

Outcome of interest

Exposure of interest

	+	ı
+	a	b
-	С	d

$$RR = \frac{a/(a+b)}{c/(c+d)}$$